Cereno Scientific reports six activated clinical sites and updated timeline in the Phase II study in PAH with drug candidate CS1
Cereno Scientific (XSAT: CRNO B) today announced that six clinical sites across the US are activated and actively recruiting patients in the ongoing Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1. To date, two patients have been randomized and entered the treatment period. An amendment to the study protocol is now in effect with the aim to primarily broaden the patient inclusion criteria and simplify the screening process while preserving high-quality data in the study. The study’s top-line results are expected in mid-2023 based on the adjusted timeline caused